Tenet Healthcare (NYSE:THC) Upgraded to Strong-Buy at Wall Street Zen

Key Points

• Wall Street Zen upgraded Tenet Healthcare (NYSE:THC) from a "buy" to a "strong-buy" in a recent research note.
• Tenet beat Q1 EPS expectations with $4.82 EPS vs. $4.21 consensus, gave FY2026 EPS guidance of 16.38–18.68, while revenue was roughly in line with estimates.
• Despite mostly positive analyst ratings (average price target $241.94), several firms trimmed price targets and insiders sold about 46,517 shares worth $10.94M in the past three months, indicating some caution.

Tenet Healthcare (NYSE:THC - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a research report issued on Sunday.

THC has been the subject of a number of other reports. Wells Fargo & Company decreased their price objective on Tenet Healthcare from $265.00 to $213.00 and set an "overweight" rating for the company in a research report on Friday. KeyCorp decreased their price objective on Tenet Healthcare from $250.00 to $225.00 and set an "overweight" rating for the company in a research report on Friday. Jefferies Financial Group increased their price objective on Tenet Healthcare from $250.00 to $265.00 and gave the stock a "buy" rating in a research report on Thursday, February 12th. UBS Group increased their price objective on Tenet Healthcare from $260.00 to $288.00 and gave the stock a "buy" rating in a research report on Thursday, February 12th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Tenet Healthcare in a research report on Wednesday, March 4th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $241.94.

Tenet Healthcare Stock Up 3.5%

Shares of NYSE:THC opened at $183.23 on Friday. The business has a fifty day moving average of $207.31 and a two-hundred day moving average of $204.27. The stock has a market cap of $16.05 billion, a P/E ratio of 9.53, a PEG ratio of 1.37 and a beta of 1.30. The company has a quick ratio of 1.68, a current ratio of 1.36 and a debt-to-equity ratio of 1.96. Tenet Healthcare has a 52-week low of $145.27 and a 52-week high of $247.21.

Tenet Healthcare (NYSE:THC - Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The company reported $4.82 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.21 by $0.61. Tenet Healthcare had a return on equity of 25.55% and a net margin of 7.94%.The firm had revenue of $5.37 billion for the quarter, compared to the consensus estimate of $5.39 billion. During the same quarter last year, the business posted $4.36 EPS. The firm's quarterly revenue was up 2.6% compared to the same quarter last year. Tenet Healthcare has set its FY 2026 guidance at 16.380-18.68 EPS. On average, research analysts expect that Tenet Healthcare will post 17.42 earnings per share for the current year.

Insider Activity

In other news, EVP Thomas W. Arnst sold 8,000 shares of the firm's stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $238.85, for a total value of $1,910,800.00. Following the completion of the sale, the executive vice president directly owned 12 shares of the company's stock, valued at $2,866.20. This trade represents a 99.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider R. Scott Ramsey sold 8,017 shares of Tenet Healthcare stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $232.70, for a total value of $1,865,555.90. The SEC filing for this sale provides additional information. Insiders sold 46,517 shares of company stock valued at $10,943,111 in the last three months. 0.81% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Tenet Healthcare

Hedge funds and other institutional investors have recently bought and sold shares of the company. NewEdge Advisors LLC increased its position in Tenet Healthcare by 6.1% during the first quarter. NewEdge Advisors LLC now owns 2,890 shares of the company's stock worth $389,000 after buying an additional 166 shares in the last quarter. Jones Financial Companies Lllp increased its position in Tenet Healthcare by 299.1% during the first quarter. Jones Financial Companies Lllp now owns 1,700 shares of the company's stock worth $229,000 after buying an additional 1,274 shares in the last quarter. Sivia Capital Partners LLC purchased a new position in Tenet Healthcare during the second quarter worth $290,000. Quantbot Technologies LP purchased a new position in Tenet Healthcare during the second quarter worth $65,000. Finally, Amundi increased its position in Tenet Healthcare by 4,207.8% during the second quarter. Amundi now owns 27,010 shares of the company's stock worth $4,652,000 after buying an additional 26,383 shares in the last quarter. 95.44% of the stock is owned by institutional investors and hedge funds.

Key Tenet Healthcare News

Here are the key news stories impacting Tenet Healthcare this week:

• Positive Sentiment: Q1 earnings beat and solid profitability — Tenet reported $4.82 EPS, well ahead of consensus, and showed healthy margins and ROE; investors favor the earnings beat even though revenue was roughly in-line. Tenet Healthcare (THC) Q1 Earnings Top Estimates
• Positive Sentiment: Strategic growth via ASC acquisitions — Tenet deployed ~$125M to acquire seven ambulatory surgery centers in Q1 and signals more M&A in the outpatient space, supporting revenue diversification and higher-margin outpatient growth. Tenet deployed $125M on 7 ASC acquisitions in Q1, eyes more deals
• Positive Sentiment: Operational momentum in procedures and robotics — The company is seeing double‑digit joint replacement growth and expanding robotic programs across ASCs/hospitals, evidence that its outpatient acuity push is producing revenue mix benefits longer term. Double-digit joint replacement growth
• Neutral Sentiment: Analysts trimmed price targets but kept Buy/Outperform/Overweight ratings — Multiple firms cut PTs (RBC to $236, Guggenheim to $252, Wells Fargo to $213, KeyCorp to $225) while retaining positive ratings, which gives the stock continued sell‑side endorsement but signals more conservative valuation assumptions. Analyst price target coverage (Benzinga summaries) TickerReport coverage
• Neutral Sentiment: Market commentary and investor takeaways — Several pieces are advising investors to weigh analyst views and the company’s outpatient strategy at current levels; these articles are shaping investor positioning rather than delivering new fundamental news. Seeking Alpha: Investor commentary
• Negative Sentiment: Revenue softness and admissions‑mix headwinds — Management flagged admissions mix and external disruptions as reasons revenue missed expectations modestly; that weak revenue signal tempers the EPS beat and is the main near-term risk. Tenet Healthcare Blames Admissions Mix For Soft Q1 Sales

About Tenet Healthcare

Tenet Healthcare Corporation NYSE: THC is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet's operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.